Effekten av ultralydbehandling i kombinasjon med kortikosteroid intraartikulær injeksjon for artritt
This study investigates whether ultrasound therapy applied prior to intra-articular corticosteroid injection can enhance the treatment efficacy for patients with joint arthritis and assess its safety. Adult patients diagnosed with arthritis in the limbs who are indicated for corticosteroid injection are eligible, while patients with joint replacement, hip joint involvement, gout, infectious arthritis, or local cellulitis are excluded.
Ultrasound therapy is a valuable physical therapy tool for musculoskeletal diseases, producing therapeutic effects through thermal and non-thermal mechanisms. It can improve tissue extensibility, reduce joint stiffness, increase local blood flow, enhance metabolism during tissue repair, and facilitate drug absorption. This study evaluates whether applying ultrasound before intra-articular corticosteroid injection improves therapeutic outcomes in patients with arthritis, and assesses the safety of this combined intervention. Patients aged 18 or older, diagnosed with limb arthritis, and indicated for corticosteroid injection are eligible. Exclusion criteria include joint replacement, hip joint involvement, gout, infectious arthritis, or local cellulitis at the treatment site.
Studieoversikt
Status
Status
Forhold
Forhold
Intervensjon / Behandling
Intervensjon / Behandling
Studietype
Studietype
Registrering (Antatt)
Registrering
Fase
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
Studiekontakt
- Navn: Kuo-Lung Lai, MD
- Telefonnummer: +886-4-2359-2525
- E-post: kllaichiayi@yahoo.com.tw
Studiesteder
-
-
-
Taichung, Taiwan, 407219
- Rekruttering
- Taichung Veterans General Hospital
-
Ta kontakt med:
- Kuo-Lung Lai, MD
- Telefonnummer: +886-4-2359-2525
- E-post: kllaichiayi@yahoo.com.tw
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Adults aged 18 years or older.
- Diagnosed with arthritis in the limbs.
- Inadequate response to or contraindication for oral anti-inflammatory medications.
- Assessed by a physician as requiring intra-articular corticosteroid injection.
Exclusion Criteria:
- History of joint replacement (prosthetic joint) in the affected area.
- Hip joint involvement.
- Diagnosis of gout.
- Infectious arthritis.
- Presence of cellulitis at the treatment site.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Antall våpen
Våpen og intervensjoner
Deltakergruppe / ArmDeltakergruppe / Arm |
Intervensjon / BehandlingIntervensjon / Behandling |
|---|---|
|
Eksperimentell: ultralydbehandling i kombinasjon med kortikosteroid intraartikulær injeksjon
|
Therapeutic Ultrasound (TUS) is a non-invasive treatment widely used in physical medicine and rehabilitation for musculoskeletal conditions. Since its introduction in the mid-20th century, TUS has gained popularity in clinical practice due to its ability to penetrate tissues, target treatment areas precisely, and exhibit minimal side effects. This study aims to investigate the mechanisms of action, clinical efficacy, and safety of therapeutic ultrasound in musculoskeletal therapy. Injection of triamcinolone (3-50 mg depending on joint size) into the affected joint. Administered once per participant. |
|
Aktiv komparator: kortikosteroid intraartikulær injeksjon
|
Injection of triamcinolone (3-50 mg depending on joint size) into the affected joint. Administered once per participant. |
Hva måler studien?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Reduction in Synovial Swelling Area Assessed by Joint Ultrasound
Tidsramme: From enrollment to the end of treatment at 2 weeks
|
Synovial swelling area (pixels) assessed by joint ultrasound. A treatment response is defined as a ≥50% reduction in synovial swelling area from baseline. |
From enrollment to the end of treatment at 2 weeks
|
|
Change in Power Doppler (PD) Score of the Target Joint
Tidsramme: From enrollment to the end of treatment at 2 weeks
|
Power Doppler (PD) score (range 0-3) of the target joint assessed by joint ultrasound. A treatment response is defined as a PD score of 0 at 2 weeks post-treatment. |
From enrollment to the end of treatment at 2 weeks
|
|
Change in Pain Visual Analogue Scale (VAS)
Tidsramme: From enrollment to the end of treatment at 2 weeks
|
Pain intensity assessed using a visual analogue scale (VAS 0-10). A treatment response is defined as a ≥50% reduction in VAS score from baseline or a VAS score ≤1 at 2 weeks post-treatment. |
From enrollment to the end of treatment at 2 weeks
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Absence of Synovitis Recurrence Based on Power Doppler (PD) Score
Tidsramme: From enrollment to 3 months post-treatment
|
Absence of synovitis recurrence assessed by Power Doppler (PD) ultrasound. Recurrence is defined as any increase in PD score compared with the 2-week post-treatment assessment. |
From enrollment to 3 months post-treatment
|
|
Absence of Synovial Swelling Recurrence on Gray-Scale Ultrasound
Tidsramme: From enrollment to 3 months post-treatment
|
Absence of synovial swelling recurrence assessed by gray-scale ultrasound. Recurrence is defined as an increase in synovial swelling area of ≥20% compared with the 2-week post-treatment assessment. |
From enrollment to 3 months post-treatment
|
Samarbeidspartnere og etterforskere
Sponsor
Sponsor
Etterforskere
Etterforskere
- Hovedetterforsker: Kuo-Lung Lai, MD, Taichung Veterans General Hospital (TaichungVGH)
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Studiestart
Primær fullføring (Antatt)
Primær fullføring
Studiet fullført (Antatt)
Studiet fullført
Datoer for studieregistrering
Først innsendt
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Først lagt ut
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Sist oppdatering lagt ut
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
Andre studie-ID-numre
- TCVGH-1150801B
- CF25511A (Annen identifikator: TCVGH IRB)
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .